The Economic Burden of Asthma Prior to Death: a Nationwide Descriptive Study

Overview

Journal Front Public Health

Specialty Public Health

Date 2024 Mar 5

PMID 38439749

Authors

Laurent Guilleminault

Michael Mounie

Agnes Sommet

Claire Camus

Alain Didier

Laurent Lionel Reber

Cecile Conte

Nadege Costa

Affiliations

Soon will be listed here.

Abstract

Background: In addition to the clinical burden, asthma is responsible for a high economic burden. However, little is known about the economic burden of asthma prior to death.

Objective: We performed an economic analysis to describe the costs during 12 and 24 months prior to asthma death between 2013 and 2017 in France.

Methods: An observational cohort study was established using the French national health insurance database. Direct medical and non-medical costs, as well as costs related to absence from the workplace, were included in the analysis.

Results: In total, 3,829 patients were included in the final analysis. Over 24 and 12 months prior to death, total medical costs per patient were €27,542 [26,545-28,641] and €16,815 [16,164-17,545], respectively. Total medical costs clearly increased over 24 months prior to death. Over 12 months prior to death, costs increased significantly according to age categories, with mean total costs of €8,592, €15,038, and €17,845, respectively, for the categories <18 years old, 18-75 years old, and 75+ years old ( < 0.0001). Over 12 months prior to death, costs were statistically higher in patients with a dispensation of six or more SABA canisters compared to those with a dispensation of five or less canisters ( < 0.0001). In multivariate analysis, comorbidities, hospital as location of death, and dispensation of 12 or more canisters of SABA per year are independent factors of the highest costs.

Conclusion: To conclude, the economic burden of asthma death is high and increases with time, age, and SABA dispensation.

References

OByrne P, FitzGerald J, Bateman E, Barnes P, Zhong N, Keen C . Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. N Engl J Med. 2018; 378(20):1865-1876. DOI: 10.1056/NEJMoa1715274. View

Bateman E, Price D, Wang H, Khattab A, Schonffeldt P, Catanzariti A . Short-acting β-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. Eur Respir J. 2021; 59(5). PMC: 9068976. DOI: 10.1183/13993003.01402-2021. View

Nurmagambetov T, Kuwahara R, Garbe P . The Economic Burden of Asthma in the United States, 2008-2013. Ann Am Thorac Soc. 2018; 15(3):348-356. DOI: 10.1513/AnnalsATS.201703-259OC. View

Settipane R, Kreindler J, Chung Y, Tkacz J . Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States. Ann Allergy Asthma Immunol. 2019; 123(6):564-572.e3. DOI: 10.1016/j.anai.2019.08.462. View

Roche N, Nadif R, Fabry-Vendrand C, Pillot L, Thabut G, Teissier C . Asthma burden according to treatment steps in the French population-based cohort CONSTANCES. Respir Med. 2022; 206:107057. DOI: 10.1016/j.rmed.2022.107057. View

Raherison-Semjen C, Guilleminault L, Billiart I, Chenivesse C, De Oliveira A, Izadifar A . Updated guidelines (2021) for management and follow-up of asthmatic patients of the French Society of Pneumology (SPLF) and the French Society of Pediatric Pneumology and Allergology (SP2A). Short version. Respir Med Res. 2022; 81:100898. DOI: 10.1016/j.resmer.2022.100898. View

Sullivan P, Slejko J, Ghushchyan V, Sucher B, Globe D, Lin S . The relationship between asthma, asthma control and economic outcomes in the United States. J Asthma. 2014; 51(7):769-78. DOI: 10.3109/02770903.2014.906607. View

Chen W, Safari A, FitzGerald J, Sin D, Tavakoli H, Sadatsafavi M . Economic burden of multimorbidity in patients with severe asthma: a 20-year population-based study. Thorax. 2019; 74(12):1113-1119. DOI: 10.1136/thoraxjnl-2019-213223. View

Beasley R, Holliday M, Reddel H, Braithwaite I, Ebmeier S, Hancox R . Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. N Engl J Med. 2019; 380(21):2020-2030. DOI: 10.1056/NEJMoa1901963. View

10.

Quint J, Arnetorp S, Kocks J, Kupczyk M, Nuevo J, Plaza V . Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America. J Allergy Clin Immunol Pract. 2022; 10(9):2297-2309.e10. DOI: 10.1016/j.jaip.2022.02.047. View

11.

Souza-Machado C, Souza-Machado A, Franco R, Ponte E, Barreto M, Rodrigues L . Rapid reduction in hospitalisations after an intervention to manage severe asthma. Eur Respir J. 2009; 35(3):515-21. DOI: 10.1183/09031936.00101009. View

12.

Ebmeier S, Thayabaran D, Braithwaite I, Benamara C, Weatherall M, Beasley R . Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012). Lancet. 2017; 390(10098):935-945. DOI: 10.1016/S0140-6736(17)31448-4. View

13.

Nwaru B, Ekstrom M, Hasvold P, Wiklund F, Telg G, Janson C . Overuse of short-acting β-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020; 55(4). PMC: 7160635. DOI: 10.1183/13993003.01872-2019. View

14.

Stroupe K, Gaskins D, Murray M . Health-care costs of inner-city patients with asthma. J Asthma. 1999; 36(8):645-55. DOI: 10.3109/02770909909055416. View

15.

Guilleminault L, Mounie M, Sommet A, Camus C, Didier A, Reber L . Healthcare resource consumption prior to asthma-related death: a nationwide descriptive study. Ther Adv Respir Dis. 2022; 16:17534666221130217. PMC: 9577087. DOI: 10.1177/17534666221130217. View

16.

Tupper O, Ulrik C . Long-term predictors of severe exacerbations and mortality in a cohort of well-characterised adults with asthma. Respir Res. 2021; 22(1):269. PMC: 8529759. DOI: 10.1186/s12931-021-01864-z. View

17.

Bateman E, Reddel H, OByrne P, Barnes P, Zhong N, Keen C . As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. N Engl J Med. 2018; 378(20):1877-1887. DOI: 10.1056/NEJMoa1715275. View

18.

Shaw D, Gaynor C, Fogarty A . Changes in asthma mortality in England and Wales since 2001. Thorax. 2019; 74(12):1174-1175. DOI: 10.1136/thoraxjnl-2019-213350. View

19.

Chen W, Lynd L, FitzGerald J, Marra C, Balshaw R, To T . Excess medical costs in patients with asthma and the role of comorbidity. Eur Respir J. 2016; 48(6):1584-1592. DOI: 10.1183/13993003.01141-2016. View

20.

Tavakoli H, Fitzgerald J, Chen W, Lynd L, Kendzerska T, Aaron S . Ten-year trends in direct costs of asthma: a population-based study. Allergy. 2016; 72(2):291-299. DOI: 10.1111/all.12993. View